The GRID2 gene is associated with Spinocerebellar Ataxia Type 18 (SCA18), a rare genetic disorder characterized by progressive coordination and balance problems due to degeneration of the cerebellum. This condition is inherited in an autosomal recessive manner, meaning that an individual must receive a defective gene from each parent to be affected.
Testing for mutations in the GRID2 gene is crucial for diagnosing SCA18, enabling accurate genetic counseling, and facilitating management plans for affected individuals. The genetic test involves analyzing DNA to identify mutations in the GRID2 gene that are known to cause the disorder.
At DNA Labs UAE, a specialized test for the GRID2 gene associated with Spinocerebellar Ataxia Type 18 is available, helping in the early diagnosis and management of the condition. The cost of the test is 4400 AED. This comprehensive testing service provides vital information for affected families, offering insights into the genetic basis of the condition and the risk of passing it on to future generations.
The ATXN2 gene spinocerebellar ataxia type 2 (SCA2) autosomal dominant genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ATXN2 gene, which are known to cause spinocerebellar ataxia type 2. This condition is a neurodegenerative disorder characterized by progressive coordination problems, difficulty walking, and other neurological symptoms due to degeneration of the cerebellum and its connections. Since SCA2 is inherited in an autosomal dominant manner, having just one copy of the altered gene is sufficient to cause the disorder.
The test is crucial for individuals with a family history of SCA2 or those exhibiting symptoms suggestive of the condition. Early detection through genetic testing can aid in the management of symptoms, genetic counseling, and informing family planning decisions. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect mutations in the ATXN2 gene.
DNA Labs UAE offers this genetic test, providing a comprehensive analysis for those at risk of or suspected to have spinocerebellar ataxia type 2. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately. Conducted in a state-of-the-art facility, the test adheres to high standards of quality and confidentiality, ensuring reliable and secure results for patients and their families.
The TMEM240 Gene Spinocerebellar Ataxia Type 21 Autosomal Dominant Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE. This test is designed to identify mutations in the TMEM240 gene, which have been linked to Spinocerebellar Ataxia Type 21 (SCA21), a rare genetic disorder. SCA21 is characterized by progressive coordination problems, difficulty walking, and other neurological symptoms due to cerebellar atrophy. As an autosomal dominant condition, having just one copy of the mutated gene from either parent is sufficient to cause the disorder.
The genetic test involves analyzing the patient's DNA to check for specific mutations in the TMEM240 gene that are responsible for SCA21. Early diagnosis through genetic testing can be crucial for the management of symptoms and understanding the risk of transmission to future generations.
DNA Labs UAE offers this comprehensive genetic test at a cost of 4400 AED. Conducted in a state-of-the-art laboratory setting, the test provides individuals and families with critical information regarding the genetic basis of SCA21, enabling informed decisions about health and family planning.
The KCND3 gene spinocerebellar ataxia type 22 autosomal dominant genetic test is a specialized diagnostic tool designed to identify mutations in the KCND3 gene, which are linked to the development of spinocerebellar ataxia type 22 (SCA22). SCA22 is a neurological condition characterized by progressive ataxia, which includes difficulties with coordination and balance due to cerebellar degeneration. As an autosomal dominant disorder, a mutation in just one of the two copies of the gene in each cell is sufficient to cause the condition, meaning it can be directly passed from an affected parent to their child.
The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in a laboratory setting to detect mutations in the KCND3 gene. This genetic testing is crucial for individuals with a family history of SCA22 or those exhibiting symptoms, as it can confirm a diagnosis, inform treatment decisions, and help with family planning.
Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the cost of the KCND3 gene spinocerebellar ataxia type 22 autosomal dominant genetic test is set at 4400 AED. This investment in testing is essential for those seeking clarity on their genetic status concerning SCA22, enabling them and their healthcare providers to make informed decisions regarding their health and future.
The PDYN gene Spinocerebellar Ataxia Type 23 (SCA23) Autosomal Dominant Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the PDYN gene that are associated with SCA23. Spinocerebellar ataxia type 23 is a neurodegenerative disorder characterized by progressive problems with movement, typically emerging in adulthood. The condition is inherited in an autosomal dominant pattern, meaning that a mutation in just one copy of the relevant gene in each cell is sufficient to cause the disorder.
The test involves analyzing the patient's DNA to look for specific genetic changes in the PDYN gene that are known to cause SCA23. This genetic testing is crucial for the accurate diagnosis of the condition, which can help in planning the appropriate management and treatment strategies for affected individuals. Additionally, it can provide essential information for family planning and genetic counseling for families affected by SCA23.
At DNA Labs UAE, the cost of the PDYN gene Spinocerebellar Ataxia Type 23 Autosomal Dominant Genetic Test is set at 4400 AED. This comprehensive testing service not only offers a crucial diagnostic tool for patients and their families but also provides the peace of mind that comes with understanding one's genetic health landscape.
The EEF2 gene spinocerebellar ataxia type 26 (SCA26) autosomal dominant genetic test is a specialized diagnostic tool used to detect mutations in the EEF2 gene, which have been linked to SCA26. Spinocerebellar ataxia type 26 is a rare, inherited neurological disorder characterized by progressive coordination problems, difficulty walking, and other motor system impairments due to cerebellar atrophy. Since SCA26 follows an autosomal dominant inheritance pattern, having just one copy of the altered gene is sufficient to cause the disorder.
This genetic test is crucial for individuals with a family history of SCA26 or those showing symptoms suggestive of the condition. Early and accurate diagnosis through this test can aid in the management of symptoms, genetic counseling, and planning for the future.
The test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately. By opting for this test at DNA Labs UAE, patients and their families can expect reliable results, comprehensive support, and guidance on the implications of the findings for their health and lifestyle.
The FGF14 gene, associated with Spinocerebellar Ataxia Type 27 (SCA27), is a critical area of genetic study due to its implications in the development of this specific type of ataxia. Spinocerebellar ataxia is a progressive, neurodegenerative condition characterized by coordination and balance difficulties, stemming from the cerebellum's degeneration. SCA27, in particular, is distinguished by its genetic link to mutations in the FGF14 gene, which plays a significant role in the functioning of neurons in the cerebellum.
Recognizing the importance of early diagnosis and the potential for family planning and management, DNA Labs UAE offers a specialized genetic test targeting the FGF14 gene to identify mutations associated with Spinocerebellar Ataxia Type 27. This test is vital for individuals with a family history of SCA27 or those exhibiting symptoms suggestive of spinocerebellar ataxias.
The testing process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the FGF14 gene that are known to cause SCA27. This autosomal dominant condition means a single copy of the altered gene in each cell is sufficient to cause the disorder, making the identification of such mutations critical for affected families.
The cost of the FGF14 gene test for Spinocerebellar Ataxia Type 27 at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, including the sophisticated techniques used to detect genetic variations accurately, and the expertise required to interpret the results. Given the complexity of genetic testing and the potential implications of the results, genetic counseling is often recommended alongside testing to provide individuals and families with the support and information needed to understand their risk and options moving forward.
The AFG3L2 gene plays a crucial role in the development and maintenance of the nervous system. Mutations in this gene are directly linked to Spinocerebellar Ataxia Type 28 (SCA28), a rare, autosomal dominant disorder characterized by progressive ataxia, or loss of full control of bodily movements. Individuals with SCA28 may experience a range of symptoms, including difficulty with coordination and balance, speech impairments, and eye movement abnormalities. Given its genetic basis, identifying carriers or affected individuals early can be pivotal in managing the condition and understanding its progression.
DNA Labs UAE offers a specialized genetic test aimed at detecting mutations in the AFG3L2 gene to diagnose Spinocerebellar Ataxia Type 28. This test is particularly valuable for individuals with a family history of SCA28 or those exhibiting symptoms associated with the condition. By utilizing advanced genetic sequencing technologies, DNA Labs UAE provides accurate and reliable results, which are crucial for making informed decisions about treatment and management strategies.
The cost of the AFG3L2 gene test for Spinocerebellar Ataxia Type 28 at DNA Labs UAE is 4400 AED. Given the complexity of the genetic analysis and the profound impact that the results can have on patients and their families, this test represents a significant step forward in the personalized care and management of genetic disorders.
The FLRT1 gene, associated with SPG68, plays a critical role in our genetic makeup, influencing various bodily functions and developmental processes. SPG68 is a condition categorized under hereditary spastic paraplegias (HSP), which are a group of genetic disorders characterized by progressive weakness and spasticity of the legs. The FLRT1-related genetic test is a specialized diagnostic tool designed to detect mutations in the FLRT1 gene, which can help in confirming a diagnosis of SPG68.
This test is particularly important for individuals showing symptoms of HSP or those with a family history of the condition, as it can provide definitive genetic evidence of SPG68. Early diagnosis through genetic testing like the FLRT1 test can aid in the management of the condition, allowing healthcare providers to tailor treatment plans more effectively and offer genetic counseling for affected families.
The FLRT1 gene SPG68-related genetic test is available at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the comprehensive insights it offers into the individual's genetic health concerning the FLRT1 gene and SPG68. By opting for this test at DNA Labs UAE, patients and healthcare providers can expect high-quality diagnostic services, supported by advanced genetic testing technologies and expert interpretations.
The SPG7 gene is associated with a condition known as spastic paraplegia 7 (SPG7), a form of hereditary spastic paraplegia. This genetic disorder is characterized by progressive weakness and stiffness of the legs, resulting from the degeneration of nerve pathways responsible for muscle movement and sensation. The SPG7 gene encodes a protein called paraplegin, which is involved in the maintenance and function of mitochondria, the energy-producing structures within cells. Mutations in the SPG7 gene disrupt the normal function of paraplegin, leading to the symptoms associated with the condition.
To diagnose this genetic condition, an SPG7 genetic test is conducted. This test specifically looks for mutations in the SPG7 gene that are known to cause spastic paraplegia 7. It is a crucial step in confirming the diagnosis, understanding the inheritance pattern, and guiding management and treatment decisions for affected individuals and their families.
In the UAE, DNA Labs UAE offers the SPG7 genetic test. The cost of the test is 4400 AED. DNA Labs UAE is equipped with advanced genetic testing technology to ensure accurate and reliable results. By opting for this test, patients and their healthcare providers can gain valuable insights into the genetic basis of their condition, enabling a more tailored approach to treatment and management.
